Arsenic trioxide to prevent relapse after stem cell transplant
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study tests whether adding arsenic trioxide to the usual stem cell transplant procedure can lower the risk of leukemia coming back. It is for people with high-risk AML or MDS who have a specific TP53 gene change.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) and be planned for your first stem cell transplant.
- Your cancer must have a specific TP53 gene change or a loss of part of chromosome 17, which makes relapse more likely.
- You can have active disease or be in remission, as long as the blasts (immature cells) in your marrow are not more than 30%.
- You must be 21 years or older.
- Your overall health must be good enough: able to care for yourself (score 70% or more on a standard scale), with adequate heart, lung, kidney, and liver function.
- You need a fully matched (8 out of 8) unrelated donor, and the stem cells must come from peripheral blood (collected from the bloodstream).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of oral medications, including arsenic trioxide, venetoclax, and a chemotherapy agent (azacitidine or decitabine), for people with certain blood cancers (AML, MDS, or CMML) that have a TP53 gene mutation. The goal is to see if this pill-based treatment can help control the cancer.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
This trial tests a targeted radiation drug (Astatine-211) given before a donor stem cell transplant for people with high-risk leukemia or certain bone-marrow cancers. The goal is to better control the cancer before the transplant.
This trial tests a combination of three drugs (vedolizumab, cyclophosphamide, and tacrolimus) to prevent graft-versus-host disease, a common complication after a donor stem cell transplant. It is for people with certain blood cancers who are getting a reduced-intensity transplant.
This trial tests a stem cell transplant using milder chemotherapy (treosulfan and fludarabine) followed by a drug called cyclophosphamide to prevent graft-versus-host disease. It aims to make transplant safer for people with blood diseases who cannot handle standard high-dose chemotherapy.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.